The cost to develop new drugs and vaccines is growing and the success rate may be slowing. Likelihood of approval for new FDA Phase I
The cost to develop new drugs and vaccines is growing and the success rate may be slowing. Likelihood of approval for new FDA Phase I
Novartis and Roche enjoy pharma-industry leading 2024 revenues. They also lead in total international patent volume. But Roche, with more oncology-specific patents for cancer treatment